ArticleMedicine2026
Celiac disease increases the risk of pulmonary arterial hypertension: A multivariable Mendelian randomization and mediation analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Celiac disease (CeD) has been implicated in several autoimmune and vascular disorders, but its causal role in pulmonary arterial hypertension (PAH) remains uncertain. Summary-level genome-wide association study data for all traits were obtained from the FinnGen consortium and the genome-wide association study catalog, 2 publicly accessible databases integrating genetic data with health registry information. A 2-sample Mendelian randomization (MR) approach was employed to evaluate the causal effect of CeD on PAH. Univariable MR was conducted initially, and the results were validated through meta-analysis based on 2 independent cohorts. To control for possible confounding influences, multivariable MR was applied with adjustments for obesity and smoking. Mediation analyses were performed to determine whether autoimmune disorders mediated the observed association. Heterogeneity and pleiotropy were assessed to ensure the robustness of the findings. A significant causal association between CeD and PAH was identified in the univariable MR analysis (discovery cohort: odds ratio [OR] of inverse-variance weighted [IVW] [ORIVW], 1.148; 95% confidence interval [CI], 1.027-1.282; P = .015; replication cohort: ORIVW, 1.112; 95% CI, 1.043-1.186; P = .001), and this relationship was further supported by the meta-analysis of both cohorts (ORIVW, 1.136; 95% CI, 1.065-1.212; P < .001). The association remained statistically significant after adjustment for obesity and smoking in multivariable MR (ORIVW, 1.138; 95% CI, 1.011-1.281; P < .032), suggesting that the effect of CeD on PAH is independent of these factors. Among the AIDs examined, only systemic lupus erythematosus exhibited a meaningful mediating role in this causal pathway (mediation proportion [95% CI]: 30.4% [3.6%-57.2%], P < .023). No evidence of heterogeneity or horizontal pleiotropy was detected across all MR analyses (all P > .050). Genetic evidence supports that CeD increases the risk of PAH, with systemic lupus erythematosus potentially acting as a mediator. These findings provide new insights into shared autoimmune mechanisms underlying PAH and suggest that immune regulation may represent a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.